영업이익률
2005년부터
계산
Thermo Fisher Scientific Inc., 영업이익률, 장기 추세계산
| 영업이익률 | = | 100 | × | 영업이익1 | ÷ | 수익1 | |
|---|---|---|---|---|---|---|---|
| 2023. 12. 31. | 16.00% | = | 100 | × | 6,859) | ÷ | 42,857) |
| 2022. 12. 31. | 18.69% | = | 100 | × | 8,393) | ÷ | 44,915) |
| 2021. 12. 31. | 25.57% | = | 100 | × | 10,028) | ÷ | 39,211) |
| 2020. 12. 31. | 24.19% | = | 100 | × | 7,794) | ÷ | 32,218) |
| 2019. 12. 31. | 17.99% | = | 100 | × | 4,594) | ÷ | 25,542) |
| 2018. 12. 31. | 15.53% | = | 100 | × | 3,783) | ÷ | 24,358) |
| 2017. 12. 31. | 14.19% | = | 100 | × | 2,968) | ÷ | 20,918) |
| 2016. 12. 31. | 13.40% | = | 100 | × | 2,449) | ÷ | 18,274) |
| 2015. 12. 31. | 13.77% | = | 100 | × | 2,336) | ÷ | 16,965) |
| 2014. 12. 31. | 14.82% | = | 100 | × | 2,503) | ÷ | 16,890) |
| 2013. 12. 31. | 12.30% | = | 100 | × | 1,610) | ÷ | 13,090) |
| 2012. 12. 31. | 11.85% | = | 100 | × | 1,482) | ÷ | 12,510) |
| 2011. 12. 31. | 10.62% | = | 100 | × | 1,245) | ÷ | 11,726) |
| 2010. 12. 31. | 11.72% | = | 100 | × | 1,265) | ÷ | 10,789) |
| 2009. 12. 31. | 10.38% | = | 100 | × | 1,049) | ÷ | 10,110) |
| 2008. 12. 31. | 11.71% | = | 100 | × | 1,229) | ÷ | 10,498) |
| 2007. 12. 31. | 10.00% | = | 100 | × | 974) | ÷ | 9,746) |
| 2006. 12. 31. | 6.38% | = | 100 | × | 242) | ÷ | 3,792) |
| 2005. 12. 31. | 10.01% | = | 100 | × | 263) | ÷ | 2,633) |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
1 US$ 단위: 백만 달러
경쟁사와의 비교
Thermo Fisher Scientific Inc., 영업이익률, 장기 추세, 경쟁사와의 비교
| Thermo Fisher Scientific Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| 2023. 12. 31. | 16.00% | 23.49% | 29.35% | 21.77% | 28.24% | 30.85% | 38.83% |
| 2022. 12. 31. | 18.69% | 31.21% | 38.57% | 27.61% | 27.17% | 38.93% | 48.23% |
| 2021. 12. 31. | 25.57% | 31.89% | 31.44% | 25.35% | 36.72% | 55.67% | 36.73% |
| 2020. 12. 31. | 24.19% | 24.81% | 37.70% | 18.99% | 16.72% | 42.09% | 46.03% |
| 2019. 12. 31. | 17.99% | 39.03% | 43.57% | 18.25% | 19.38% | 28.10% | 28.77% |
| 2018. 12. 31. | 15.53% | 19.49% | 45.55% | 17.11% | 37.83% | 37.77% | 20.84% |
| 2017. 12. 31. | 14.19% | 33.99% | 45.76% | 16.48% | 55.04% | 35.41% | 4.95% |
| 2016. 12. 31. | 13.40% | 36.60% | 44.74% | 16.29% | 58.87% | 27.38% | 0.58% |
| 2015. 12. 31. | 13.77% | 32.97% | 40.44% | 16.87% | 69.03% | 30.51% | -45.23% |
| 2014. 12. 31. | 14.82% | 17.09% | 32.03% | 17.23% | 62.37% | 29.74% | -119.30% |
| 2013. 12. 31. | 12.30% | 30.14% | 32.25% | 17.13% | 41.87% | 36.11% | -74.54% |
| 2012. 12. 31. | 11.85% | 31.65% | 33.52% | 17.33% | 42.67% | 33.20% | 0.15% |
| 2011. 12. 31. | 10.62% | — | 28.19% | 16.27% | 46.77% | -46.02% | 8.07% |
| 2010. 12. 31. | 11.72% | — | 37.82% | 16.41% | 53.62% | -21.23% | -485.51% |
| 2009. 12. 31. | 10.38% | — | 38.37% | 13.79% | 54.55% | -19.54% | -602.63% |
| 2008. 12. 31. | 11.71% | — | 35.50% | 14.72% | 52.68% | -37.67% | -263.65% |
| 2007. 12. 31. | 10.00% | — | 27.81% | 15.79% | 57.98% | -91.55% | -210.94% |
| 2006. 12. 31. | 6.38% | — | 27.71% | 15.82% | -29.32% | -169.68% | -105.86% |
| 2005. 12. 31. | 10.01% | — | 40.33% | 15.84% | 61.41% | -187.97% | -93.15% |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).